This Slide: #39 of 100 |
Slide #39. AtriCure — Endoscopic Technologies, Inc. d/b/a Estech
Acquirer:
AtriCure (NASDAQ:ATRC)
Acquiree:
Endoscopic Technologies, Inc. d/b/a Estech
Details:
AtriCure, Inc. (NASDAQ:ATRC), a leading Atrial Fibrillation (Afib) medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech ("Estech"), today announced that they have entered into a definitive merger agreement under which AtriCure has agreed to acquire Estech for a cash-free, debt-free up-front payment of approximately 2.1 million shares or $34 million of AtriCure common stock and up to $26 million in additional consideration based on the achievement of certain revenue-based milestones. The transaction is subject to customary closing conditions and is expected to close in the next several weeks. AtriCure shareholder approval is not required.
AtriCure provides treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain. Co.'s ablation and left atrial appendage management products are used by physicians during both open-heart and minimally invasive procedures. Co.'s Isolator® Synergy Ablation System is approved by U.S. Food and Drug Administration (FDA) for the treatment of persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures. The EPi-Sense® system is approved by FDA to treat patients with long-standing persistent Afib. All of Co.'s other ablation devices are cleared for sale in U.S., including its other radio frequency and cryoablation products.
ATRC SEC Filing Email Alerts Service
Open the ATRC Page at The Online Investor »
|
Open the ATRC Page at The Online Investor (in a new window) »
Free ATRC Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.67 out of 4) 67th percentile
(ranked higher than approx. 67% of all stocks covered)
Analysts' Target Price: ATRC Stock Forecast Based on Zacks ABR data; powered by Xignite |